Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 20/20 | 0.61 |
| ▸ | LATS2 | Q9NRM7 | 17/20 | 0.61 |
| ▸ | PRKCH | P24723 | 1/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344402 | 0.90 | LATS1 (0.55) | LATS1LATS2 | |
| SCHEMBL20299238 | 0.86 | LATS1 (0.49) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL3461416 | 0.82 | MAPT (0.59) | — | |
| SCHEMBL19880866 | 0.80 | LATS1 (0.63) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL9979356 | 0.79 | NPC1 (0.43) | LATS1LATS2 | |
| SCHEMBL15644179 | 0.79 | LATS1 (0.61) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL21875480 | 0.79 | LATS1 (0.61) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20548138 | 0.78 | LATS1 (0.43) | LATS1LATS2 | |
| SCHEMBL14344413 | 0.77 | KMT2A (0.50) | LATS1 | |
| SCHEMBL1234101 | 0.77 | ACHE (0.41) | LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621222-B | 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | GENENTECH, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347594-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | Genentech, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3615537-B1 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| CN-117425654-A | 2, 8-diazaspiro [4.5] decane compounds | 基因泰克公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| CN-110573511-B | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | B2M, EPAS1, LATS2 | LATS1 5/4885LATS2 3/4885PRKCH 1043/4885 |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | LATS1 1164/4885LATS2 1387/4885PRKCH 6/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | LATS1 1083/4885LATS2 1287/4885PRKCH 8/4885 |
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | LATS1, LATS2, GLS2 | LATS1 1/4885LATS2 2/4885PRKCH 2257/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCH 1778/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | LATS1 900/4885LATS2 1220/4885PRKCH 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.